- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01783509
Limb Girdle Muscular Dystrophy (LGMD) Natural History
April 20, 2022 updated by: Wake Forest University Health Sciences
Longitudinal Assessment and Genetic Understanding of Limb-Girdle Muscular Dystrophy
The purpose of this study is to understand more about limb-girdle muscular dystrophy.
Therefore, the investigators would like to track the following information collected once a year from patients with GENETICALLY CONFIRMED LGMD: quality of life questionnaires, muscle strength, motor function, routine examination, assessment of patient (or parent) understanding of LGMD, and serum (blood) for growth factors, cytokines, and biomarkers (all parts of your blood).
By tracking this information, we hope to be able to understand more about the diagnosis, progression and natural history of this disorder.
Study Overview
Status
Completed
Study Type
Observational
Enrollment (Actual)
13
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28203
- Carolinas Medical Center - Pediatrics
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients with a diagnosis of GENETICALLY CONFIRMED LGMD
Description
Inclusion Criteria:
- You have a GENETICALLY CONFIRMED diagnosis of Limb Girdle Muscular Dystrophy
- You must be at least 6 years of age or older (if under 18 you will need Parental consent)
- You must be able to travel to the study site
- You must be able to provide a DNA/Gene testing report that confirms a diagnosis of LGMD
Exclusion Criteria:
- You or your child do not have a diagnosis of LGMD
- Your child is under age 6
- You or your child are not able to travel to the study site
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
|---|
|
LGMD
Patients with GENETICALLY CONFIRMED limb girdle muscular dystrophy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Comprehensive clinical evaluation of individuals with GENETICALLY CONFIRMED LGMD, according to the study protocol, in order to evaluate disease progression
Time Frame: yearly up to 10 years
|
yearly up to 10 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Ibrahim Binalsheikh, MD, Carolinas Medical Center - Pediatrics
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2011
Primary Completion (Actual)
July 1, 2017
Study Completion (Actual)
July 1, 2017
Study Registration Dates
First Submitted
January 18, 2013
First Submitted That Met QC Criteria
February 1, 2013
First Posted (Estimate)
February 5, 2013
Study Record Updates
Last Update Posted (Actual)
April 28, 2022
Last Update Submitted That Met QC Criteria
April 20, 2022
Last Verified
July 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LGMD Nat Hx
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Muscular Dystrophies, Limb-Girdle (GENETICALLY CONFIRMED)
-
University Hospital of North NorwayUniversity of Tromso; Norwegian Muscle Disease Association (FFM); Norwegian National... and other collaboratorsActive, not recruitingMuscular Dystrophies | Limb Girdle Muscular Dystrophy | Limb Girdle Muscular Dystrophy, Type 2I | Limb Girdle Muscular Dystrophy R9 FKRP-relatedNorway
-
Assistance Publique - Hôpitaux de ParisRecruitingLimb Girdle Muscular DystrophiesFrance
-
Lindsay AlfanoCompletedLimb-Girdle Muscular Dystrophy Type 2A | Limb-Girdle Muscular Dystrophy, Type 2EUnited States
-
Sarepta Therapeutics, Inc.WithdrawnMuscular Dystrophies, Limb-GirdleUnited States
-
Nationwide Children's HospitalNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaboratorsCompletedLimb-Girdle Muscular DystrophyUnited States
-
aTyr Pharma, Inc.CompletedLimb-Girdle Muscular Dystrophies | Facioscapulohumeral Muscular DystrophyUnited States, Denmark, France
-
PTC TherapeuticsTerminatedLimb-Girdle Muscular DystrophyUnited States, Norway, Canada, Sweden, Russian Federation, Denmark, France, Germany
-
Rigshospitalet, DenmarkCompletedLimb-girdle Muscular DystrophyDenmark
-
IRCCS San Camillo, Venezia, ItalyUniversita di Verona; Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico and other collaboratorsEnrolling by invitationCalpain-3 Deficiency Limb Girdle Muscular Dystrophy Type 2AItaly
-
Virginia Commonwealth UniversityUniversity of Colorado, Denver; Washington University School of Medicine; University... and other collaboratorsActive, not recruitingLimb Girdle Muscular Dystrophy | Calpain-3 Deficiency Limb Girdle Muscular Dystrophy Type 2A | Limb Girdle Muscular Dystrophy Type R1 | LGMD2AUnited States